The present invention refers to a microbial composition comprising probiotic microorganisms, adjuvants and an acceptable carrier. The composition of the invention is stable and shows efficacy in reducing the incidence of diarrhea in calves and also achieves a significant increase in their body weight.

An object of the present invention is to provide a fermented product containing equol-producing microorganisms in the state of living cells by which equol production ability is maintained. When producing a fermented material by using an equol-producing microorganism, with soybean powder or soybean milk as raw materials, (1) preparing a mother starter by fermentation under anaerobic conditions by using an equol-producing microorganism in the presence of a daidzein species at pH 5.0 or higher, (2) preparing a bulk starter by fermentation under anaerobic conditions by using said mother starter in the presence of a daidzein species at pH 5.0 or higher, and (3) preparing a fermented material by fermentation by using said bulk starter in a medium containing soybean powder or soybean milk, enables production of a fermented material containing microorganisms in the state of living cells in which the equol production ability is maintained.

The present invention relates to a fermented infant formulae comprising non digestible oligosaccharides for improving intestinal tract health by decreasing protein digestive effort, by decreasing the amount of endogenously formed proteases concomitant with an increased protein digestion, and a reduced protein fermentation.

The present invention relates to a fermented infant formulae comprising non digestible oligosaccharides for improving intestinal tract health by decreasing protein digestive effort, by decreasing the amount of endogenously formed proteases concomitant with an increased protein digestion, and a reduced protein fermentation.

The present invention relates to a fermented infant formulae comprising non digestible oligosaccharides for improving intestinal tract health by decreasing protein digestive effort, by decreasing the amount of endogenously formed proteases concomitant with an increased protein digestion, and a reduced protein fermentation.

The present invention relates to a fermented infant formulae comprising non digestible oligosaccharides for improving intestinal tract health by decreasing protein digestive effort, by decreasing the amount of endogenously formed proteases concomitant with an increased protein digestion, and a reduced protein fermentation.

The subject invention pertains to the use of certain bacterial strains, particularly butyrogenic bacteria, for preparing a composition to treat and/or prevent Clostridium difficile infection. In particular, the invention relates to the use of butyrate-producing anaerobic fermenters of gut commensals in pharmaceutical or food compositions.

It is to provide a fermentation composition comprising live bacteria of lactic acid bacteria, etc. at a certain concentration (cfu/mL) or more and having a pH in a neutral range, in which fermentation composition an increase in sour taste and odor, a decrease in pH, and/or a decrease in the live bacteria concentration (cfu/mL) of lactic acid bacteria, etc. during refrigerated storage after the production are suppressed, and a method of producing the fermentation composition, and so on. It is related to a fermentation composition having a pH of 6.0 to 7.4, the composition comprising: (a) 110.sup.6 cfu/mL or more of live bacteria of one or more types of bacteria selected from the group consisting of lactic acid bacteria and bacteria of the genus Bifidobacterium; (b) a milk raw material and/or a fermented product using a milk raw material; and (c) dead bacterial cells of bacteria of the genus Lactococcus, and a method of producing the fermentation composition, and so on.

The present disclosure relates to a method of altering intestinal microbiome in a patient having cystic fibrosis comprising administering at least one of Bifidobacterium and/or Bacteroides to a patient and allowing the Bifidobacterium and/or Bacteroides to alter the intestinal microbiome.

The present disclosure relates to a method of altering intestinal microbiome in a patient having cystic fibrosis comprising administering at least one of Bifidobacterium and/or Bacteroides to a patient and allowing the Bifidobacterium and/or Bacteroides to alter the intestinal microbiome.